Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06196840
PHASE2

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Sponsor: Innostellar Biotherapeutics Co.,Ltd

View on ClinicalTrials.gov

Summary

The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.

Official title: A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Key Details

Gender

All

Age Range

50 Years - 89 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2024-01-24

Completion Date

2029-10

Last Updated

2026-03-06

Healthy Volunteers

No

Interventions

GENETIC

LX102 subretinal injection

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

BIOLOGICAL

Aflibercept intravitreal injection

Commercially available Active Comparator

Locations (11)

Anhui Provincial Hospital

Hefei, Anhui, China

Zhejiang University Eye Hospital

Hangzhou, Zhejiang, China

Peking Union Medical College Hospital

Beijing, China

West China Hospital of Sichuan University

Chengdu, China

Guangzhou Aier Eye Hospital

Guangzhou, China

Zhongshan Ophthalmic Center of Sun Yat-Sen University

Guangzhou, China

Shanghai Eye and ENT Hospital

Shanghai, China

Shanghai General Hospital

Shanghai, China

Shanxi Eye Hospital

Taiyuan, China

Tianjin Medical University Eye Hospital

Tianjin, China

Xuzhou No.1 People's Hospital

Xuzhou, China